Search results: Found 7

Listing 1 - 7 of 7
Sort by
Perspektiven für ein Europäisches Urheberrecht

Author:
Book Series: Abhandlungen zum Urheber- und Kommunikationsrecht ISBN: 9783845254890 Year: Volume: 58 Pages: 536 DOI: http://dx.doi.org/10.5771/9783845254890 Language: de
Publisher: Nomos Verlagsgesellschaft mbH & Co. KG
Subject: Law
Added to DOAB on : 2018-11-05 12:58:39
License:

Loading...
Export citation

Choose an application

Abstract

Die Arbeit untersucht die Möglichkeit der Schaffung eines Europäischen Urheberrechts als Verordnung. Nach einer Analyse der Kompetenzen der Union im Urheberrecht vergleicht der Verfasser die bisher verfolgte Harmonisierungsmethode mittels Richtlinien mit einer möglichen Unionsurheberrechtsverordnung. Sodann geht er der Frage nach, welche materiellrechtlichen Bereiche des Urheberrechts vor dem Hintergrund der Kompetenzen der Union Teil einer Urheberrechtsverordnung sein könnten. Schließlich untersucht er, ob eine Urheberrechtsverordnung zwingend die nationalen Urheberrechte verdrängen müsste oder ob nicht eine Parallelität von Unionsurheberrecht und nationalen Urheberrechten möglich ist.

Patent Strategy in Pharmaceutical Industry: Are additional patents valuable?

Author:
Book Series: Munich Intellectual Property Law Center – MIPLC ISBN: 9783845251288 Year: Volume: 20 Pages: 84 DOI: http://dx.doi.org/10.5771/9783845251288 Language: en
Publisher: Nomos Verlagsgesellschaft mbH & Co. KG
Subject: Law
Added to DOAB on : 2018-11-05 12:58:39
License:

Loading...
Export citation

Choose an application

Abstract

This book investigates lifecycle management strategies used by pharmaceutical companies attempting to maximize the value of their product portfolio. Such strategies are sometimes referred to by generic drug companies as “evergreening”. The analysis focuses on two of these strategies, namely product improvements and product line extensions. In particular, an evaluation of the patents that follow the basic one and that accompany the development of a drug from research to market is attempted. Two “blockbuster” drugs, Taxotere and Xalatan, were randomly chosen to carry out such analysis. The patent portfolio of the originator companies is outlined and some important patents for each area of research (e.g. formulations, combinations, delivery devices) are shortly described. Patent filing trends for the two drugs, both in regards of the originator and in regards of other competing companies (amongst these also the generics) are schematically shown.

The Ownership Problems of Overlaps in European Intellectual Property

Author:
Book Series: Munich Intellectual Property Law Center - MIPLC ISBN: 9783845254494 Year: Volume: 21 DOI: http://dx.doi.org/10.5771/9783845254494 Language: en
Publisher: Nomos Verlagsgesellschaft mbH & Co. KG
Subject: Law
Added to DOAB on : 2018-11-05 12:58:39
License:

Loading...
Export citation

Choose an application

Abstract

Intellectual Property rights are expanding and, thus, overlapping more than ever before. This poses challenges to a system devised as comprising a set of isolated compartments, each with its defined purpose.

Second Generation Patents in Pharmaceutical Innovation

Author:
Book Series: Munich Intellectual Property Law Center – MIPLC ISBN: 9783845250861 Year: Volume: 19 Pages: 355 DOI: http://dx.doi.org/10.5771/9783845250861 Language: en
Publisher: Nomos Verlagsgesellschaft mbH & Co. KG
Subject: Law
Added to DOAB on : 2018-11-05 12:58:39
License:

Loading...
Export citation

Choose an application

Abstract

The development of new medications and improvements thereof are crucial to ensure continued gains in health. The development process is long and costly, and mainly to produce the information to meet high regulatory requirements. In contrast, imitation involves negligible costs and much reduced risks. This is one of the reasons the pharmaceutical industry depends greatly on patent protection. Despite the existing patent system, however, the number of new medications per year has decreased, especially during the last decade. In comparison, the number of second generation patents and products has been drastically increased. This industry is accused both of neglecting its real mission of providing new medications while generating second generation products, and of preventing the entry of generics. The dissertation reviewed whether the concerns are justified, and, if so, whether or how the patent system can improve the situation that confronts pharmaceutical companies and society.

Bioethics and the Patent Eligibility of Human Embryonic Stem Cells-Related Inventions in Europe

Author:
Book Series: Munich Intellectual Property Law Center - MIPLC ISBN: 9783845255149 Year: Volume: 22 DOI: http://dx.doi.org/10.5771/9783845255149 Language: en
Publisher: Nomos Verlagsgesellschaft mbH & Co. KG
Subject: Law
Added to DOAB on : 2018-11-05 12:58:39
License:

Loading...
Export citation

Choose an application

Abstract

The topic of this book is one of the most contentious, complex and at the same time very important in many respects. Latest achievements in the biotechnology industry related to the stem cell technology are quite important.

Haftung für den Missbrauch von Zugangsdaten im Internet

Author:
Book Series: Internet und Recht ISBN: 9783845255910 Year: Volume: 14 Pages: 500 DOI: http://dx.doi.org/10.5771/9783845255910 Language: de
Publisher: Nomos Verlagsgesellschaft mbH & Co. KG
Subject: Law
Added to DOAB on : 2018-11-05 12:58:39
License:

Loading...
Export citation

Choose an application

Abstract

Mit einem bei der Diskussion oft fehlendem Blick auf die technischen Grundlagen untersucht der Autor die Haftung des Account-Inhabers für missbräuchliche Handlungen eines Dritten über Accounts im Internet. Neben der materiellen Frage der Haftung auf Erfüllung oder Schadensersatz behandelt die Arbeit die prozessuale Frage von Beweiserleichterungen. Dabei richtet er den Blick auf Benutzerkonten auf Internetseiten ebenso wie auf E-Mail-Adressen, die elektronische Signatur, den elektronischen Identitätsnachweis im neuen Personalausweis sowie die De-Mail.

Community Collective Marks: Status, Scope and Rivals in the European Signs Landscape

Author:
Book Series: Munich Intellectual Property Law Center – MIPLC ISBN: 9783845256467 Year: Volume: 23 Pages: 68 DOI: http://dx.doi.org/10.5771/9783845256467 Language: en
Publisher: Nomos Verlagsgesellschaft mbH & Co. KG
Subject: Law
Added to DOAB on : 2018-11-05 12:58:39
License:

Loading...
Export citation

Choose an application

Abstract

This book looks into the nature and status of Community collective marks and explores to what extent they can incorporate certification marks under the current European trade mark law. Welcoming the proposal for a new European Trade Mark Regulation in 2013, the study argues that the two genres should be distinguished from one another, serving distinct purposes. Further, the significance and role of Geographical Indications under the European Union Law are addressed, as well as the question of whether they need to be kept as a separate regime. Although the advantages of each sign are obstructed by discrepancies in terminologies and confusion in legal theory and practice, the author examines the potential of each system by analysing the CTMR as it stands and the OHIM practice, comparing them to national legislations and elucidating the intention of the European legislator.

Listing 1 - 7 of 7
Sort by
Narrow your search

Publisher

Nomos Verlagsgesellschaft mbH & Co. KG (7)


License

CC by (6)

CC by-nc-nd (1)


Language

en (5)

de (2)


Year
From To Submit

2014 (7)